compname reports third quarter results and announces new investment from chairman and chief executive officer Rick Rick Rick.
quarterly guidance has been reduced.
quarterly adjusted earnings per share growth of approximately 15%.
qtrly fy2022 results in early and late stage lung cancer care improvement results included significant headwinds due to covid-19 clinical trial delays.
compname reports third quarter 2021 results.
compname posts quarterly results for 2021 and announces new $2 billion share repurchase program and reinstatement of $1 billion share dividend.
compname reports q3 results; on average, 75% of patients receiving risankizumab in both studies achieved pasi 90 compared to 42% and 48% of patient received stelara.
compname reports fourth quarter results and announces second quarter 2021 results.
qtrly total net sales $2.89 billion versus refinitiv ibes estimate of $2,619.8 million.
qtrly results (on an adjusted basis, saw very high levels of efficacy in the first time of the initiated trial compared to humira.
qtrly revenues of $1.5 billion versus $1,712.9 million.
severe case of indigestion, after 16 weeks, were re-randomized to risankizumab or humira.
q2 pasi 90 patient average net sales rose 66% to $92 million from $66.7 million.
company's pipeline remains on track to see positive results from ongoing trial of psoriasis-significant clinical trial early next year.
for six indications, upadacitinib is expected to be commercialized in 2019.
noted previously announced top line results from second phase iii studies, the select-beyond study.
